January 11, 2005 -- Biotech stocks followed or perhaps, led the market lower on Tuesday, as the market looked at the less-than-overwhelming results in Genentech (DNA), and sold off the entire sector. The Centient Biotech 200 dropped a whopping 2.8%, moving lower by 98.09 points to close at 3382.70. We look at Genentech’s numbers, Dendreon’s failed Phase III test, MGI Pharma’s cash flow, and Regeneron’s downgrade--offset by the continued rise in stem cell stocks...
